Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments
- 1 December 2007
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 57 (6) , 972-976
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Placebo Theory and Its Implications for Research and Clinical Practice: A Review of the Recent LiteraturePain Practice, 2007
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis & Rheumatism, 2005
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's DiseaseScience, 2001
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulationNature, 1999